Sunday, September 20, 2020
Home Health News VitalPatch granted EUA for monitoring COVID-19 patients' QT intervals

VitalPatch granted EUA for monitoring COVID-19 patients’ QT intervals

The FDA has granted an Emergency Use Authorization (EUA) to VitalConnect that allows its VitalPatch wearable sensor to further monitor patients undergoing COVID-19 treatment.

As per the agency’s letter of authorization, providers may use the remote-monitoring device in a hospital setting to spot changes in patients’ QT interval, which may be dangerously prolonged by experimental drug treatments such as hydroxychloroquine or chloroquine.

Part of VitalConnect’s broader Vista Solution continuous-monitoring platform, VitalPatch is a disposable adhesive wearable that can be used for seven days straight. It’s capable of tracking eight vital signs (or 11 with the aid of compatible third-party devices) in real time, such as single-lead ECG, heart rate and heart rate variability, activity, and respiratory rate.


In making its decision, FDA said that it considered the need for vital sign and ECG monitoring among those at risk for complications related to COVID-19 or its potential treatments. The EUA for VitalConnect fills a need for remote patient-monitors capable of detecting QT interval changes, the agency wrote, and does so while potentially reducing healthcare providers’ exposure to the virus.

“COVID-19 presents a myriad of symptoms and clinicians need access to medical devices that allow them to monitor and manage those symptoms in real-time in order to create the most appropriate treatment plans for each individual,” Dr. Joe Roberson, CMO of VitalConnect, said in a statement. “The enhancement of the VitalPatch receiving [EUA] for QT-interval detection will enable this platform to further support clinicians who are on the frontlines of treating this virus.”  


The FDA has had its eye on remote vital-sign monitors since mid-March, when it announced a temporary policy that would expand the use of certain connected non-invasive devices throughout the course of the COVID-19 public health emergency. Since then, VitalConnect, Livongo, Abbott and other digital-health mainstays announced plans to expand access to their connected health-monitoring products.

And connected vitals monitors haven’t been the only types of digital health products to benefit from relaxed regulatory guidelines. Ophthalmologic devices, digital psychiatric treatments and telehealth at large have all been provided an opportunity to reach more patients throughout the public health crisis.


“As we learn more about the novel coronavirus, the VitalPatch and Vista Solution platform can make a big impact on the treatment of the many people suffering across our nation,” Peter Van Haur, CEO of VitalConnect, said in a statement. “Continuous, real-time monitoring enables next-level care and efficiency in the hospital and in post-discharge settings that will help clinicians treating patients on the frontlines today.”

Source link


Please enter your comment!
Please enter your name here

Also Read This

Ascensia picks up global commercialization & distribution of Senseonics’ Eversense CGMs

Continuous glucose monitoring (CGM) system-maker Senseonics has cut a deal with Ascensia Diabetes Care and its parent company, PHC Holdings, outlining commercialization and distribution of...

Trump to decide what the Republican National Convention will look like amid COVID-19 – National

After months of insisting that the Republican National Convention go off as scheduled despite the pandemic, U.S. President Donald Trump is slowly coming to...

Truepill scores $75M in Series C funding and looks to roll out at-home testing services

Just two months after closing its Series B funding, Truepill, a digital pharmacy that focuses on APIs, telehealth practitioners and pharmacy fulfillment services, announced a new $75...

Ontario reports 323 new coronavirus cases, 17 deaths as total cases top 27,500

Posted May 30, 2020 10:42 am Smaller font Descrease article font size -A Larger font Increase article font size A+


COVID-19 Precautions 

  • Wash your hands frequently .
  • Maintain social distancing,
  • Avoid touching eyes, nose and mouth.
  • Practice respiratory hygiene.